Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ideaya Biosciences (NASDAQ: IDYA).The analyst commented, "HARMONi-3 skepticism may be ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE